Between 10 and 20 million people worldwide are infected with the human T-cell lymphotropic virus type 1 (HTLV-1). Despite causing life-threatening pathologies there is no therapeutic regimen for this deltaretrovirus. Here, we screened a library of integrase strand transfer inhibitor (INSTI) candidates built around several chemical scaffolds to determine their effectiveness in limiting HTLV-1 infection. Naphthyridines with substituents in position 6 emerged as the most potent compounds against HTLV-1, with XZ450 having highest efficacy in vitro. Using single-particle cryo-electron microscopy we visualised XZ450 as well as the clinical HIV-1 INSTIs raltegravir and bictegravir bound to the active site of the deltaretroviral intasome. The structures reveal subtle differences in the coordination environment of the Mg^{2+} ion pair involved in the interaction with the INSTIs. Our results elucidate the binding of INSTIs to the HTLV-1 intasome and support their use for pre-exposure prophylaxis and possibly future treatment of HTLV-1 infection.
Human T-cell lymphotropic virus type 1 (HTLV-1) is a deltaretrovirus and one of the most oncogenic human viruses. It is the causative agent of a severe form of blood cancer called adult T-cell leukaemia/lymphoma (ATLL) and a range of debilitating neuromuscular disorders—HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP), which often lead to paralysis. Although only 5–10% of the estimated 10–20 million people infected with HTLV-1 worldwide will develop ATLL, a recent report showed that the vast majority of otherwise asymptomatic patients suffer from issues that severely impact their quality of life, including pain, discomfort and depression. 12.7% of HAM/TSP patients reported their quality of life was worse than death, based on the Euroqol five dimension questionnaire (EQ-5D).

HTLV research has largely remained in the shadow of HIV research, which has moved at a much faster pace. Like HIV-1, HTLV-1 is a blood-borne pathogen that is transmitted horizontally by contact with infected blood, sexual intercourse and vertically from mother to child during breastfeeding and labour. The likelihood of an HTLV-1 carrier developing ATLL is correlated most commonly during breastfeeding or child-birth. The prevailing dogma is that, following the initial exposure early in life, HTLV-1 replication is primarily the result of the clonal proliferation of infected cells. However, recent data indicate there is ongoing viral replication, which leads to the generation of additional clones of HTLV-1 infected cells, and increases the proviral load. An increased viral load is correlated with an increased risk of developing HTLV-1-associated malignancy and inflammatory disease. Hence, suppression of additional rounds of viral infection may reduce the risk of malignant transformation. Administering anti-retroviral agents may help prevent HTLV-1 transmission among drug users, serodiscordant couples, organ recipients and pregnant/breastfeeding mothers. Thus, strong arguments can be made for developing HTLV-targeted therapeutics. Integration of a DNA copy of the viral genome is an essential step in the replication of all retroviruses. Integrase strand transfer inhibitors (INSTIs) are among the most effective anti-HIV drugs. Similarly, understanding the integrase (IN) enzyme of HTLV, and how it can be inhibited, will be a critical part of the effort to control HTLV infections. We recently reported that the first- and second-generation HIV INSTIs are effective at inhibiting HTLV-1 strand transfer in vitro and integration in tissue culture. In this report, we have characterised several groups of INSTIs that have been reported to inhibit the replication of HIV.

The target of the INSTIs is the IN active site engaged with viral DNA (vDNA) ends in the context of the nucleoprotein complex termed the intasome. Technical advances in cryogenic electron microscopy (cryo-EM), recently allowed the structural characterisation of HIV-1 intasomes in complexes with clinical and experimental INSTIs at near-atomic resolution. Currently, no structural information is available on the mode of INSTI binding to the deltaretroviral intasome. We recently determined the cryo-EM structure of the deltaretroviral simian T-cell lymphotropic virus type 1 (STLV-1) intasome bound to its host factor B56y. Here, in addition to characterising three compounds that block HTLV-1 transmission two- to fivefold more potently than raltegravir (RAL), we report three high-resolution cryo-EM structures of a deltaretroviral intasome bound to three different INSTIs. The 3D reconstructions allow for direct comparison between the binding modes of these inhibitors in lentiviral and deltaretroviral intasomes. Our findings have important implications for establishing therapies targeted at HTLV-1 and provides a framework for understanding the mechanism of INSTI action on the HTLV-1 intasome at the atomic scale.

Results

XZ450 is a potent HTLV-1 inhibitor. We evaluated a library of 32 small molecules collectively comprising five classes of known and candidate INSTIs, including naphthyridines, pyridinones, diketo acids, oxoisoindoles and hydrazines (Supplementary Table 1). Most of the compounds were 4-, 6- and 7-substituted naphthyridines, some of which had previously shown remarkable potency against wild-type and mutant forms of HIV-1 IN, including the Q148H/G140S RAL-resistant and dolutegravir-resistant (G118R, T66I, E92Q, R263K, H51Y or H51/R263K) mutants. Long aliphatic or aromatic substituents at the 6-position are able to reach across the active site pocket, and associate with the protein backbone as shown in the crystal structures of PFV and cryo-EM reconstructions of HIV-1 intasomes. We also included naphthyridines designed to inhibit HIV RNase H that were not previously tested against IN, because the compounds also target a pair of magnesium ions in the active site, which is similar to INSTI binding. Cross inhibition has previously been found with hydrazines and other INSTIs, which effectively blocked herpes simplex virus replication by inhibiting RNase H-like fold containing proteins.

We used in vitro strand transfer assays to screen this small molecule library for its ability to inhibit recombinant HTLV-1 IN. The enzyme was incubated with an oligonucleotide vDNA donor mimic in the presence or absence of INSTIs and was allowed to react with a supercoiled plasmid mimicking target DNA. During the screening, the concentration of each compound was adjusted to 634 nM to provide optimal resolution of efficacy between well- and under-performing compounds. Summarised in Fig. 1a, the results show that all of the 6-substituted naphthyridines we tested are more potent inhibitors of HTLV-1 IN compared with RAL. In addition, one 4-substituted naphthyridine (XZ378) and one pyridinone (XZ236) also outperformed RAL.

These observations were corroborated using strand transfer assays to obtain dose–response relationships and IC_{50} values (Fig. 1b and Supplementary Fig. 4). Within this panel of selected compounds, the IC_{50} values were two- to fourfold lower than that of RAL, with the exception of XZ420 and XZ278, which showed no significant improvement over RAL. Overall, compounds XZ450, XZ446 and XZ448 exhibited the best characteristics, displaying IC_{50} values of 120.2 ± 36.1 nM, 115.4 ± 9.5 nM and 131.1 ± 29.7 nM, respectively, compared with 410 ± 78.5 nM of RAL (Supplementary Table 2). The three compounds are 4-amino-substituted naphthyridines featuring all of which have an additional extended substitution at 6-position with a 3-(dimethylamino)-3-oxopropyl, phenylsulfonyl ethyl or hydroxyethylaminooxopropyl group, respectively (Supplementary Table 1).

Six of the most promising compounds were selected for assessment of their efficacy in inhibiting HTLV-1 viral infection. To this end, we employed an MT-2-Jurkat co-culture relying on cell-to-cell-based HTLV-1 transmission, which we successfully used in a previous study. In this assay format, the infection of Jurkat cells is measured via real-time quantitative PCR (qPCR) determination of the proviral load (PVL). In line with our in vitro data, XZ450 and XZ446 were most potent in inhibiting HTLV-1 infection of Jurkat T cells (Fig. 1c, and Supplementary Fig. 5), exhibiting ~2.5- to fivefold improvements in EG_{50} (1.67 ± 1.52 nM and 2.57 ± 0.81 nM, respectively) compared with RAL (6.42 ± 4.24 nM). A block in the integration reaction was confirmed by Alu-qPCR experiments (Supplementary Fig. 6). As shown previously, although bictegravir (BIC) is only about twofold more efficient in blocking HTLV-1 integrase strand transfer in vitro, BIC potently blocks HTLV-1 transmission in tissue culture, exhibiting a 20-fold improvement in EG_{50} (0.3 ± 0.173 nM) compared with RAL. We suspect this is owing to a more efficient uptake of BIC than RAL by Jurkat T cells.
Interestingly, XZ448, which was more potent than RAL in our in vitro strand transfer reactions exhibited ~20-fold lower activity in blocking HTLV-1 infection compared with RAL (see Discussion).

Structural studies of STLV-1 intasome:INSTI complexes by cryo-EM. During our previous work on the apo structure of the deltaretroviral intasome, we identified that the simian variant STLV-1 IN assembled into stable intasomes with greater efficiency than the HTLV-1 counterpart. This is potentially explained by the stronger binding observed between STLV-1 IN and B56γ (Supplementary Fig. 7), the latter being essential for the formation of stable intasomes in vitro. Crucially, HTLV-1 and STLV-1 INs are 83% identical by amino-acid sequence, sharing 100% identity within their active sites. Comparison of the two deltaretroviral intasome cryo-EM structures shows a remarkable overlap (Supplementary Fig. 8). Concordantly, similar to HTLV-1 IN, STLV-1 IN is highly sensitive to RAL (Supplementary Fig. 9). STLV-1 IN has also been reported to cause clinical manifestations in macaques that are similar to those seen in HTLV-1-infected patients. STLV-1-infected macaques are therefore a useful animal model for HTLV-1 infected humans. Collectively, these observations validate STLV-1 IN as an accurate and robust model for HTLV-1 IN structural drug studies.

Our previous work showed that there was a time-dependent disassociation of the STLV-1 intasome, which necessitated quick grid freezing. Low numbers of class-forming particles per micrograph led to long collection times. This was not conducive to producing multiple intasome:drug complexes at near-atomic resolution. The affinity of the endogenous binding partners for PP2A-B56 is regulated by phosphorylation at the Ser residue following the hydrophobic Leu in the LxxIxE Short Linear Motif (SLiM). Deltaretroviral INs (SLiM residues 213LxxIxE218) harbour a Pro at this position, we thus investigated whether mutating Pro214 to a phosphomimetic Asp could increase the affinity between IN and B56γ. Moreover, a previous report showed that peptides in which additional acidic residues (Glu) were added immediately following the SLiM sequence, had significantly higher affinity for B56. We thus mutated IN Ala219 into Glu. Approximately twofold more B56γ was recovered in pull-down assays when IN(A219E) was used as a bait compared with WT IN (Supplementary Fig. 10a). In contrast, there was only a minor increase in the amount of B56γ recovered with IN(P214D). The IN(A219E) mutant also formed approximately twice as much stable intasome complexes in an electrophoretic mobility shift assay (Supplementary Fig. 10b). This, together with the addition of the INSTI to freshly assembled intasomes considerably improved sample stability (Supplementary Fig. 10c). As expected, the introduction of the A219E mutation in STLV-1 IN did not change its INSTI-binding properties and produced a nearly identical IC50 for RAL compared with wild-type STLV-1 IN (Supplementary Fig. 9).

Overall, the improvements in sample stability and optimisation of the graphene oxide (GO) grid support (the latter increasing...
both the particle concentration and the distribution in particle orientation) allowed us to obtain three STLV-1 intasome: INSTI complexes, with FDA-approved INSTIs RAL and BIC, and XZ450, which was the most promising INSTI candidate identified in our screen (Fig. 2a–c and Supplementary Figs. 11–13 and Supplementary Table 6). Cryo-EM maps of the intasome:INSTI complexes were refined to an overall resolution of 3.1 Å in the case of RAL complex, 3.5 Å for BIC and 3.0 Å for XZ450. The local cryo-EM map resolution around the active site region extended to ~2.8 Å, 3.0 Å and 2.5 Å, respectively. The quality of the 3D reconstructions allowed for unambiguous placement and building of the INSTI compounds within the intasome binding pocket (Supplementary Fig. 14). The STLV-1 intasome:INSTI structures showed, as we previously reported, a twofold symmetric IN dimer of dimers with the two B56γ molecules that laterally flank the intasome (Fig. 2d, e). All 4 IN chains and their 12 structural domains are resolved remarkably well within the respective cryo-EM maps. We previously reported that all four SLiM motifs in IN are involved in binding the two B56γ molecules. The SLiM peptide belonging to the outer (non-catalytic) IN subunit binds B56γ in the canonical SLiM-binding site. At the same time, the inner (catalytic) IN SLiM engages an additional highly conserved site on B56γ. In the current intasome structures, the mutant E219 residue is seen facing the canonical SLiM-binding site on B56γ in the outer intasome chain and the IN catalytic core domain (CCD) of a neighbouring IN, in the inner IN chain (Supplementary Fig. 15). Putative interactions with neighbouring residues such as K240 or H243 on B56γ likely play a role in the stabilisation provided by the A219E mutation.

**Binding mode of INSTIs to the STLV-1 intasome.** During retroviral integration, the intasome inserts both ends of the viral genome into host DNA in two separate strand transfer reactions. The twofold symmetrical arrangement of retroviral intasomes catalyses the two transestification events resulting in the concerted integration of both ends of the vDNA into the host DNA. As in most transposases, the catalytic site is defined by the Asp-Asp-Glu catalytic triad (D65, D122 and E158 in HTLV and STLV INs), which coordinates two catalytically essential Mg$^{2+}$ ions. The metal ions are resolved in the STLV intasome: INSTI structures (Fig. 3a). The binding of RAL to the intasome is largely mediated by strong interactions between the three co-planar oxygen atoms of the drug and the Mg$^{2+}$ cations. Parallel π-π stacking of RAL’s fluorobenzyl ring against the penultimate 3′-cytosine in STLV vDNA and interactions between the oxadiazole and Y149 strengthen the binding (Fig. 3b).

As observed in previously reported intasome: INSTI structures, INSTI binding is accompanied by a flip of the terminal vDNA 3′-adenosine, which vacates a pocket formed between a dC:dG basepair and a 310 helix (IN residues 151–155 in STLV and HTLV-1 INs). The pocket becomes occupied by the fluorobenzyl group of the drug, whereas the displaced adenosine base forms parallel π-π stacking interaction with the heterocyclic backbone of the drug (Fig. 3c, d). As shown in Fig. 3d, when compared with the apo form of the STLV-1 intasome, the penultimate vDNA cytosine, which is stacked against the terminal adenine in the apo form, makes a π-π stacking interaction with the halobenzyl ring of RAL; however, the position of the cytidine is very similar in the two structures.

BIC, a second-generation INSTI, lacks the oxadiazole substituent and features an extended scaffold that allows it to span the IN active site (Fig. 4). The interaction with Y149 (Y143 in HIV), which is an important contributor to the binding of RAL, is largely absent. Because second-generation INSTIs do not form strong contacts with Y143 in HIV-1 IN, these compounds can be used to treat HIV-1 infections that involve viruses that carry resistance mutations at this position. This suggests that if an HTLV RAL-resistant Y149 mutant arose, it is very likely that the mutant would be sensitive to BIC. The position of BIC within the binding pocket brings the terminal heterocycle into proximity with the IN/CCD β4–a2 where it has close interactions with the backbone atoms of residues N123 and G124 (Fig. 4 and Supplementary Fig. 16). The corresponding residues of the HIV-1 and SIVrcm INs (N117 and G118) were recently also reported to play a role in the binding of second-generation INSTIs to the primate lentiviral intasomes.
Fig. 3 Close-up of the active site of STLV-1 intasome (red) in a complex with RAL (grey). a–b Overall structure of the complex with the cryo-EM map (cyan) overlaid. Magnesium ions are shown as green spheres. c–d Superposition of the STLV-1 intasome:RAL complex (red) on the previously reported apo form of the STLV-1 intasome (PDB ID: 6Z2Y; blue). The DNA of the intasome:apo structure is shown in gold. RAL is shown as sticks with the carbon atoms in grey. dA, deoxyadenosine; dC, deoxycytidine; RAL, raltegravir.

Fig. 4 STLV-1 intasome:INSTI complex structures. a View of the active site with the three INSTI structures overlaid binding to the STLV-1 intasome. Magnesium ions are coloured green. For clarity, the true positioning of the INSTIs is shown in the context of the intasome:RAL complex structure only (grey) which is shown in surface view (a) and sticks (b). c–e Active sites of all three complete intasome:INSTI complex structures are shown in cartoon with side chains as sticks. Magnesium ions are coloured according to the colour of the rest of the model. The drugs are shown as sticks, with the carbon atoms of RAL in magenta, BIC in purple and XZ450 in cyan. dA, deoxyadenosine; dC, deoxycytidine; RAL, raltegravir; BIC, bictegravir.
Binding mode of XZ450 to the STLV-1 intasome. XZ450 represents a class of INSTIs built on a naphthyridine-based backbone. It is one of a chemical library of candidate INSTIs designed to fill the binding pocket to a larger extent and occupy the substrate envelope. It is thought that an inhibitor, which in addition to disabling the correct conformation of the dDNA donor, largely fills the substrate envelope, but stays within the envelope, would be more active against mutant forms of IN. XZ450 binds to the active site of the STLV intasome in a fashion similar to BIC (Fig. 4). However, due to the presence of the 3-(dimethylamino)-3-oxopropyl substitutent at position 6, it reaches much further along the active site. The 6-substituent positions itself equidistantly between the P4-a2 linker and Y149, coming in close contact (<4 Å) with the backbone and side-chain atoms of both regions (Supplementary Fig. 17). Y149 is shifted significantly closer to the drug, compared with its position in the RAL- and BIC-bound intasome structures (Fig. 4b).

Similarities to other retroviral intasome:INSTI complexes. Despite the fact that retroviral integrases, in general, share a well-conserved active site, previous structural research has shown that even small changes in the conformation of active site residues can significantly affect the binding and efficacy of INSTIs14,15. The mode of binding of some INSTIs has also been shown to differ between the HIV-1 and PFV intasomes14. We, therefore, analysed the similarities in STLV-1 and HIV-1 intasomes in the conformations of the residues in the active sites, the positions of Mg2+ co-factors and the positions of RAL, BIC and XZ450/XZ419. Since HIV-1 intasome:RAL complex structure is not available, we used the PFV intasome:RAL crystal structure3 instead. We also used the structure of the complex between HIV-1 intasome and XZ419 (a close analogue of XZ450) because the structure of the HIV-1 intasome with XZ450 bound is not available.

The conformations of the bound INSTIs and their surrounding active site residues are very similar within STLV-1, HIV-1 and PFV intasome structures (Fig. 5). Undoubtedly, this is the reason for the high sensitivity of HTLV-1 to various INSTIs originally designed to inhibit HIV-1 IN (this and previous25,26 studies). STLV-1 IN residue Y149 (corresponding to Y143 and Y202 in HIV-1 and PFV, respectively) exhibits the largest difference. The tyrosine side-chain twists, displacing the terminal oxygen atom of Y149 by 4 Å in the STLV-1 intasome structure compared with the HIV-1 structure. However, there are differences in the conformation of Y149 in different STLV intasome:INSTI complexes (Fig. 4b).

Discussion

Having evaluated 32 compounds, we identified two small molecules, XZ450 and XZ446, which are two- to fivefold more potent than RAL in blocking HTLV-1 infection in viral culture. Interestingly, EC50 values for these compounds in previously reported studies of infection by wild-type HIV-1 did not show an improvement in inhibition over RAL (4 ± 2 nM for RAL compared with 5 ± 1.3 nM for XZ450)19. The inhibitory potency of XZ446 for HIV-1 (2 ± 0.1 nM)16 was similar to that for HTLV-1 (2.57 ± 0.81 nM). This illustrates that small changes within the active site can have a significant effect on the binding and efficacy of inhibitors. XZ448 activity was much less potent in its ability to inhibit HIV-1 replication (263 ± 52 nM)11 similar to our results with HTLV-1. We suspect this could be due to the less efficient uptake of XZ448 by the cells.

The architecture of the deltaretroviral intasome most closely resembles the structure of the PFV intasome, both are IN tetramers13. The binding of several classes of INSTIs to the PFV intasome has been structurally characterised and used as a model of INSTI binding to the HIV-1 intasome for the last 10 years10,11,26–30. However, it was recently reported by Lyumkis et al.14 that the binding of some INSTIs can differ between PFV and HIV. For example, the sulfenyl benzyl group of the 6-substituted naphthyridine compound XZ446 (4f) is rotated by over 90° within the binding pocket of HIV intasome compared with that bound in PFV, resulting in association with a different set of IN residues14. This underlines the importance of structural characterisation of INSTI binding specifically for the clinically important virus HTLV-1. The nearly identical conformation of the INSTIs RAL, BIC and XZ450 bound to STLV-1 IN, HIV-1 IN and PFV IN explains why all three compounds, which were developed to bind to HIV-1 IN, potently inhibit HTLV-1 replication (Fig. 1 and Supplementary Figs. 4 and 5 and Supplementary Table 2)9,25. Although the STLV-1 structures show that there is a small change in conformation of residue Y149 depending on which INSTI is bound, this difference is owing to the way the oxadiazole ring of RAL and the 3-(dimethylamino)-3-oxopropyl substitutent of XZ450 interact with the tyrosine ring. The shift of the tyrosine side chain is much more pronounced when STLV-1 and PFV intasome:RAL structures are compared (Fig. 5a inset).

Fig. 5 Similarities to other retroviral intasome:INSTI complexes. Comparison between the mode of binding of RAL (a), BIC (b) and naphthyridine-based INSTIs XZ450 and XZ419 (c) to STLV-1 and HIV-1/PVF intasomes. The inset in a shows a significant shift in the position of STLV-1 residue Y149 (not visible in the original panel). PFV and STLV-1 IN have 35.8% sequence similarity, RMSD calculations comparing active sites were calculated as described in the Methods. For PFV intasome:RAL versus STLV-1 intasome:RAL the RMSD within the active site is 1.680 Å (214 atoms to 214 atoms). b HIV-1 and STLV-1 display 40.43% sequence similarity, RMSD within the active site for the HIV-1 intasome:BIC and STLV-1 intasome:BIC structures is 4.516 Å (238 atoms to 238 atoms). c RMSD within the active site for HIV-1 intasome:XZ419 versus STLV-1 intasome:XZ450 is 2.122 Å (228 atoms to 228 atoms). The following PDB models were used: 3OYA (a), 6PUW (b) and 6V3K (c). Superpositions were conducted by the align function in PyMOL and adjusted manually if needed. dC, deoxycytidine; PFV, prototype foamy virus; RAL, raltegravir; BIC, bictegravir.
Despite the overall similarity between deltaretroviral and HIV-1 IN active sites, there are several notable differences. Thus, HIV-1 IN residues Q148 and G140 are replaced with S154 and H146 in HTLV-1 and STLV-1 INs. The Q148H/G140S substitutions in HIV-1 IN are well-known resistance mutations to the first-generation INSTIs. Cryo-EM studies of the SIVrcm Q148H/G140S intasome indicated that histidine in position 148 causes displacement of an active site water molecule coordinated by a network of hydrogen bonds involving residues Q148, E152 and D116 in the native intasome. Instead, H148 and S140 hydrogen bond each other. These changes are thought to perturb the binding of INSTIs to the intasome, yet second-generation INSTIs such as BIC are able to escape such resistance by additional interactions further along with the substrate envelope. The complex of BIC with the deltaretroviral intasome shows that there are similar interactions with the backbone of the IN α4–α2 linker (Fig. 4). We were interested in whether the presence of H146 and S154 in HTLV/STLV, albeit in reciprocal positions, would also cause displacement of the active site water molecule and therefore to some extent affect the binding of RAL. As shown in Supplementary Fig. 18, this is clearly not the case as the nucleophile the site is present, coordinated by E158 and D122, and within a reasonable distance (3.2 Å) to S154 to allow hydrogen bonding: the side chain of H146 faces away from the active site.

The structures presented here explain the high efficacy of HIV-1 INSTIs against HTLV-1 and, as such, are of obvious clinical importance. The inhibitory potencies of the many compounds in both the strand transfer and infection assays (Supplementary Table 2) will also provide a foundation for further pharmacological studies of HTLV-1. We have shown here that compound XZ450 is a potent inhibitor of HTLV-1 transmission in vitro. Pharmacokinetic studies are needed to inform us of its potency and clinical applicability. Limited data are available, but it is promising that so far, no resistance mutations have been reported that efficiently inhibit XZ450. For now, BIC appears to be the more favourable HTLV drug candidate, however, there are no data available yet on either the pharmacokinetics of BIC during pregnancy or the safety and efficacy of using BIC in pregnant women with HIV. RAL is the recommended INSTI to suppress viral load in HIV-1 pregnant women and prevent mother-to-child transmission, and no adverse effects have been found.

Given that individual INSTIs present different drug–drug interaction profiles and have different contraindications, the more INSTIs that are available that can efficiently block HTLV-1 transmission, the greater the chance of safely treating patients with INSTIs and reducing HTLV-1 spread. Although the applicability of IN-targeted treatment for the therapy of individuals who are already HTLV-1-infected remains to be verified, there is an urgent need for drugs that can be used for pre-exposure prophylaxis and early post-exposure HTLV treatment. INSTIs are not currently a standard of care for HTLV patients, even in countries where the virus is endemic. We believe our data should encourage clinical studies of INSTIs as drugs that can be used to reduce the spread of HTLV-1. Those particularly in need are pregnant and breastfeeding mothers, the partners of those who are already infected with HTLV-1, and those who are in the group of the highest risk of exposure, such as homosexual men and intravenous drug users.

### Methods

**HTLV-1, STLV-1 IN and PPP2R5C constructs for prokaryotic expression.** For expression of HTLV-1 IN, the previously described pET28a(+)–SUMO-H6–STLV-1 MarB43 IN construct was used to express wild-type STLV-1 IN (integrate sequence corresponding to nucleotides 4338–5231 of the STLV-1 MarB43 sequence). Single-point mutants of STLV-1 MarB43 IN were generated by two-step PCR splicing. The following primer pairs were used for cloning STLV-1 IN mutants: R49Q (GNNM86, GNNM770 and GNNM661, GNNM769), 147TV (GNNM662, GNNM770 and GNNM663, GNNM769), 148Q (GNNM664, GNNM770 and GNNM665, GNNM769), P214D (GNNM666, GNNM770 and GNNM667, GNNM769). The PCR products were then ligated together using primers GNNM770 and GNNM669 digested with EcoRI/XhoI and ligated into similarly digested PET28a(+)–SUMO–H6–LEDGF/IBD–PPP2R5C(S11–380) construct was used. For primer sequences, see Supplementary Table 3.

**Recombinant protein expression and purification.** HTLV-1 IN was expressed and purified by affinity, ion exchange and size exclusion chromatography. STLV-1 IN, its point mutants, and LEDGF/IBD–BS6y were expressed and purified by affinity, ion exchange and size exclusion chromatography.

**Electrophoretic mobility shift assays.** The donor DNA (vDNA) that mimics the 3’-processed LTR of STLV-1 DNA was preassembled by annealing Atto-680-labelled MarB43_U5 S30UP and MarB43_U5 S30B oligonucleotides (Supplementary Table 4) in 100 mM Tris pH 7.4, 400 mM NaCl. In all, 16 μg of STLV-1 IN or its mutants were co-incubated with 38.4 μg of LEDGF/IBD–BS6y in presence of 10 μg/mL heparin at 4 °C for 30 min to allow binding. Samples were then supplemented with 0.5 μL 20 μM Atto680-labelled vDNA, and sufficiently diluted to give a final NaCl concentration of 60 mM. This was immediately placed in a 37 °C heating block for 10 min. The sample was then returned to room temperature (RT) and any precipitate was resolubilised by the addition of NaCl to a final concentration of 1.2 M. After equilibration of the samples at RT for 10 min, the samples were either immediately supplemented with 10 μg/mL heparin or, where stated, were incubated further or additional reagents/INSTIs were added, as described. Samples, supplemented with 10 μg/mL heparin, devoid of loading dye were carefully loaded onto a 3% low melting point agarose gel containing 10 μg/mL heparin and electrophoresed, avoiding overloading. Densitometry analysis was carried out in ImageJ v1.50i. Measurements from at least three independent experiments were taken. Standard deviations and p-values were calculated in Prism 9.

**Pull-down assays.** Pull-down assays were conducted as follows: Ni-NTA resin was washed with pull-down buffer containing: 25 mM Tris-HCl pH 7.4, 150 mM NaCl, 20 mM imidazole and 0.5% CHAPS. Beads were then incubated at 4 °C for 2 h with both 10 μg of 6xHis-tagged STLV-1 MarB43 IN (or mutants thereof) and 20 μg of LEDGF/IBD–BS6y, in presence of 10 μg bovine serum albumin and pull-down buffer. The resin was subsequently washed five times with the pull-down buffer. After the last spin at 400 × g for 5 min, the supernatant was gently removed, and the beads boiled in 20 μL 1 × SDS loading buffer containing 200 mM imidazole. Samples were centrifuged and 10 μL of the supernatant was analysed on an 11% sodium dodecyl sulphate–polyacrylamide gel electrophoresis gel.

**In vitro integration strand transfer assays.** The donor DNA that mimics the 3’-processed LTR of HTLV-1 or STLV-1 DNA was preassembled by annealing the donor DNA (vDNA) and the processed LTR of HTLV-1 or STLV-1 DNA was preassembled by annealing Atto-680 labelled donor DNA and the processed LTR of STLV-1 DNA was preassembled by annealing Atto-680 labelled donor DNA and the processed LTR of HTLV-1 DNA. For HTLV-1 IN, strand transfer reactions were conducted in a solution of 24.3 mM PIPES pH 6.0, 138.4 mM NaCl, 16.6 mM MgCl2, 5.8 μM ZnCl2, 12.7 mM DTT, 0.53 μg donor DNA and 4 μg of HTLV-1 IN. In brief, the reaction was incubated at RT for 15 min in the presence of an IN ΔIBD–B56 or dimethyl sulfoxide (DMSO) control and the reaction was started by the addition of 300 ng of pGEM-9Zf(-) supercoiled plasmid DNA. The reaction was incubated for 1 h at 37 °C and stopped by adding 0.3% SDS and 25 mM ethylenediaminetetraacetic acid (EDTA), pH 8.0. For HTLV-1 IN, the reaction conditions were 25 mM RTP–HCl pH 6.0, 1 μM STLV-1 IN, 2 μM vDNA, 60 mM NaCl, 13.28 mM DTT, 10 mM MgCl2, 10 μM ZnCl2, STLV-1 IN and LEDGF/IBD–BS6y were co-incubated at the above conditions at a 2:1 molar ratio, for 4 h at 30 °C. Donor vDNA was then added and the mixture was co-incubated at 37 °C for 10 min. For INSI dose–response experiments, either the INSTI or IN ΔIBD–B56 control was then added, the sample was mixed and kept at 4 °C for an additional 15 min. Strand-transfer reactions were initiated by the addition of 300 ng of pGEM-9Zf(-) supercoiled plasmid DNA and stopped after 15 min of 37 °C incubation by adding 0.5% SDS and 25 mM EDTA, pH 8.0.

Proteins were degraded by incubation with 30 μg of proteinase K (Roche) at 37 °C for 1 h. DNA was precipitated at −20 °C overnight in the presence of ethanol supplemented with 20 μg of glycogen and then resuspended in 1.5× agarose loading dye. The DNA products were separated by electrophoresis through a 1% agarose gel. The data were analysed and the IC50 calculated as previously described. In brief, the DNA band that corresponds to the integrated conversion product was quantified by densitometry in ImageLab 4.1 (Bio-Rad). All
experiments were done in triplicate. Quantified data points were fitted to dose–response curves in Prism 9. The cumulative standard deviation for each drug was calculated as an average of the upper and lower limit values:

\[
\text{Lower limit} = \frac{IC_{50, upper}}{1.645} \\
\text{Upper limit} = \frac{IC_{50, lower}}{1.645}
\]

Where SE denotes the standard error computed by Prism 9.

**Cyto-EM grid preparation and data collection.** The STLV-1 intasome was assembled by mixing equimolar (0.03 mmol) quantities of recombinant STLV-1 IN(A219E) and LEDGF/Î·ÎµD-B56 and dialysing overnight at 4 °C against 0.5 L of 25 mM Tris-HCl pH 7.4, 200 mM NaCl, 2 mM EDTA. This sample was then concentrated at 4 °C, 1935 g in a 30-kDa MWCO ultrafiltration device (Vivapin) to a concentration of 0.2 mM. A mixture containing 0.7 mL 20 mM BTP-HCl pH 6, 10 mM CaCl₂, 10 mM DTT, 10 mM ZnCl₂, and 25 μM STLV-1 MarB_U5_S30 double-stranded vDNA (Supplementary Table 4) was placed in a heat block set to 37 °C and incubated for 10 min. The STLV-1 IN(A219E): LEDGF/Î·ÎµD-B56 4x complex was then added, mixed by gently flicking the tube and the tube placed back in the heat block for 10 min. Following incubation, the precipitate was dissolved by the addition of NaCl to a final concentration of 1.2 M, gentle mixing and a further incubation at RT for 15 min. The sample was then purified by size exclusion chromatography implemented with 50 mM INSTI (RAL, BIC, or XZ450) and 20 mM MgSO₄. The protein was then filtered to 18 Å resolution, as templates. The cryo-EM dataset was cleaned and locally reconstructed using cryoSPARC-2. Particles corresponding to half-intasome, the IN A219E mutation was introduced in the model (to estimate beam tilt and per-particles defocus) and Bayesian polishing, as implemented in MotionCor243. Contrast transfer function (CTF) parameters were estimated using Gctf-v1.0644. At this stage, images with crystalline ice contamination were discarded; 14,271 (intasome-RAL data set), 6129 (BIC) and 7719 (XZ450) particles, extracted in Relion-3.1 and binned to a pixel size of 4.4 Å, were subjected to further analysis. All the experiments were done in triplicate.

**Provincial load determination and Alu-qPCR.** The PVL was measured as previously described53,54. Jurkat genomic DNA was quantified and diluted to a concentration of 5 ng/μL. Real-time qPCR analysis was conducted on 20 ng of gDNA to measure the level of HTLV-1 (tax and gpdh) genes (Supplementary Table 5). For the standard curve, the gDNA from an HTLV-1 naturally infected T-cell clone (clone 11.50, courtesy of professor Charles Bangham), which has one copy of tax and two of gpdh, was used. The integrated provirus copy number was calculated as follows: (tax copy numbers)/(2×gpdh copy number)55, normalised to the HTLV-1 cell–to-cell infection was performed as previously described43. Jurkat T cells were counted and diluted in complete RPMI to a final concentration of 1 × 10⁶ cells/mL and plated with INSTI drug. Co-culture of 0.5 × 10⁶ for each cell line was carried out for 16 h, after which cells were washed in PBS and resuspended in 1 mL of depletion buffer (PBS, 0.1% FBS and 2 mM EGTA). MT-2 cells were depleted from the culture by means of anti-CD25 magnetic beads (DynalbeadsTM CD25, Thermo Fisher). Depletion efficiency was confirmed via flow cytometry as described previously55. Jurkat cells were cultured for 2 weeks in complete RPMI supplemented with the drugs and genomic DNA was extracted (DNeasy kit, Qiagen) and stored at −20 °C for subsequent analysis. All the experiments were done in triplicate.

**INSTI inhibitors.** Raltegravir and BIC were purchased from Adoq Bioscience (USA). The majority of the compounds shown in Supplementary Table 1 including hydrizades: XZ15, XZ45, XZ49; oxoisodioxides: XZ26, XZ90, XZ259; pyridinones: XZ202, XZ220, XZ233, XZ236; diketo acids: XZ319, XZ320 and naphthyridines: XZ231, XZ357, XZ378, XZ348, XZ413, XZ419, XZ423, XZ434, XZ439, XZ466, XZ448, XZ450, XZ452, XZ456, XZ460, XZ462 were prepared according to the references indicated in Supplementary Table 1. The preparation of compounds XZ242, XZ256 and XZ240 are discussed in Supplementary Materials and Methods. In brief, pyridinones XZ242 and XZ256 were prepared using previously reported Pummerizer cyclization deprotonation cyclodaddition cascade of imidazolines; XZ240 was prepared by a modification of our previously reported method using a combination of a suitably and naphthyridine XZ420 were prepared using previously reported method using the use of a suitably and naphthyridine XZ420 were prepared using previously reported method using the use of a suitably and naphthyridine XZ420 were prepared using previously reported method using the use of a suitably and naphthyridine XZ420 were prepared using previously reported method using the use of a suitably.

**Data availability** The cryo-EM structures have been deposited with the Protein Data Bank and EMDB and are available under the following identifiers: STLV-1 intasome: XZ450 structure: 70UF.
and EMD-13075; STLV-1 intasome: RAL structure: 70UX and EMD-13076; and STLV-1 intasome: BIC structure: 70UH and EMD-13077. Correspondence and requests for materials should be addressed to G.N.M. (g.maertens@imperial.ac.uk). Source data are provided with this paper.

Received: 6 April 2021; Accepted: 20 July 2021; Published online: 17 August 2021

References
1. Tagaya, Y. & Gallo, R. C. The exceptional oncogenicity of HTLV-1. Front. Microbiol. 8, 1425 (2017).
2. Mahieux, R. & Gessain, A. Adult T-cell leukemia/lymphoma and HTLV-1. Curr. Hematol. Malig. Rep. 2, 257–264 (2007).
3. Matsura, E. et al. HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP): a comparative study to identify factors that influence disease progression. J. Neurol. Sci. 371, 112–116 (2016).
4. Gessain, A. & Cassar, O. Epidemiological aspects and world distribution of HTLV-1 infection. Front. Microbiol. 3, 388 (2012).
5. Rosadas, C. et al. Health state utility values in people living with HTLV-1 and in patients with HAM/TSP: the impact of a neglected disease on the quality of life. PLoS Negl. Trop. Dis. 14, e0008761 (2020).
6. Carneiro-Proietti, A. B. et al. Mother-to-child transmission of human T-cell lymphotropic viruses-1/2: what we know, and what are the gaps in understanding and preventing this route of infection. J. Pediatr. Infect. Dis. Soc. 3, S24–29 (2014).
7. Laydon, D. J., Sunkara, V., Boelen, L., Bangham, C. R. M. & Asquith, B. The evolution of viral resistance. Proc. Natl. Acad. Sci. USA 107, 1910–1915 (2010).
8. Metifot, M. et al. Activities, crystal structures, and molecular dynamics of dihydرو-1H-isoindole derivatives, inhibitors of HIV-1 integrase. ACS Chem. Biol. 8, 209–217 (2013).
9. Baume, A., Rodes, B. & Soriano, V. The effect of antiretroviral therapy on HTLV-1 infection. Virus Res. 78, 93–101 (2001).
10. Hare, S. et al. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc. Natl. Acad. Sci. USA 107, 20057–20062 (2010).
11. Krishnan, L. et al. Structure-based modeling of the functional HIV-1 intasome and its inhibition. Proc. Natl. Acad. Sci. USA 107, 1910–1915 (2010).
12. Raheem, I. T. et al. Discovery of 2-pyridinone aminals: a prodrug strategy to advance a second generation of HIV-1 integrase strand transfer inhibitors. J. Med. Chem. 58, 8154–8165 (2015).
13. Schreier, J. D. et al. Discovery and optimization of 2-pyridinone aminal integrase strand transfer inhibitors for the treatment of HIV. Bioorg. Med. Chem. Lett. 27, 2038–2046 (2017).
14. Machuca, A., Rodes, B. & Soriano, V. The effect of antiretroviral therapy on HTLV-1 infection. Virus Res. 78, 93–101 (2001).
15. van der Galen, R. et al. Pharmacokinetics of HIV-integrase inhibitors during preclinical mechanisms, clinical implications and knowledge gaps. Clin. Pharmacokinet. 58, 309–323 (2019).
16. Barski, M. S. et al. Cryo-EM structure of the deltaretroviral intasome in action. Angew. Chem. Int. Ed. 132, e350 (2020).
17. Bhatt, V. et al. Structural basis of host protein hijacking in human T-cell leukemia virus type 1. Antimicrob. Agents Chemother. 55, 2011–2017 (2011).
55. Alais, S., Mahieux, R. & Dutartre, H. Viral source-independent high susceptibility of dendritic cells to human T-cell leukemia virus type 1 infection compared to that of T lymphocytes. *J. Virol.* **89**, 10580–10590 (2015).

56. Zhao, X. Z. et al. Development of tricyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors. *Bioorg. Med. Chem. Lett.* **21**, 2986–2990 (2011).

57. Zhao, X. Z. et al. Bicyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors. *Chem. Biol. Drug Des.* **79**, 157–165 (2012).

Acknowledgements

We thank Drs A. Purkiss and P. Walker for computer and software support. We thank professor C. Bangham for generously sharing with us clone 11.50. We are grateful to Pavel Afonine and Oleg Sobolev for their support in using Phenix.real_space_refine. This work is supported by the Wellcome Trust (Investigator Award to G.N.M., 107005/Z/15/Z). Work in P.C. laboratory is supported by US National Institutes of Health grant P50 AI150481 and the Francis Crick Institute (FC001061), which receives its core funding from Cancer Research UK (FC001061), the UK Medical Research Council (FC001061) and the Wellcome Trust (FC001061). Data were collected at the London Consortium Electron Microscopy Facility at The Francis Crick Institute funded by Wellcome Trust (206175/Z/17/Z to Professor Xiaodong Zhang). X.Z., S.J.S., T.R.B. and S.H.H. are supported by the NIH Intramural Program, Center for Cancer Research, National Cancer Institute and by grants from the NIH AIDS Intramural Program (IATAP). This article is independent research funded by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC). The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.

Author contributions

M.S.B. purified all wild-type and mutant proteins, assembled intasomes for biochemical analysis and cryo-EM data collection; M.S.B. and P.C. analysed the cryo-EM data; M.S.B., P.C. and V.E.P. refined the atomistic model; T.V. performed the in vitro integration assays and viral inhibition assays; X.Z.Z. and T.R.B. designed and synthesised the library of chemical compounds; S.J.S. provided guidance for choosing, among the large collection of XZ compounds, which compounds would have a good chance to be effective against HTLV/STLV; A.B.-C. prepared GO carbon and prepared the grids for cryo-EM data collection; N.B.C. collected the cryo-EM data; G.N.M. designed and guided the experiments; M.S.B., G.N.M., P.C. and S.H.H. prepared the manuscript with contributions of all authors.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-021-25284-1.

Correspondence and requests for materials should be addressed to G.N.M.

Peer review information *Nature Communications* thanks Kalyan Das and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021, corrected publication 2021